Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150

By sjmartinez • May 7, 2025

Kudo M, Yamashita T, Finn RS, Galle PR, Ducreux M, Cheng AL, Tsuchiya K, Sakamoto N, Hige S, Take R, Yamada K, Nakagawa Y, Takahashi H, Ikeda M. Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150. Liver Cancer. 2025 Mar 3:1-16. doi: 10.1159/000544981. Epub ahead of print. PMID: 40331064; PMCID: PMC12052357.

Tags: Atezolizumab plus bevacizumab, Depth of response, Duration of response, Hematology/Oncology, Hepatocellular carcinoma, overall survival, Publications

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

Muñoz J, Locke FL, Reagan PM, Goy A, Jacobson CA, Hill BT, Timmerman JM, Flinn IW, Miklos DB, Pagel JM, Kersten MJ, Forcade E, Topp[...]

Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach

Idossa D, Hennessy MA, LeVee A, Nanda R, McArthur H, Leon-Ferre RA. Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach. Am[...]

Provider Follow-Up and Adherence to Imaging Surveillance Recommendations for Lung Cancer Survivors in a Nationwide Health Care System

Wu JT, Lin N, Adams SV, Asch S, Zeliadt S, Harris AHS, Han SS, Backhus L. Provider Follow-Up and Adherence to Imaging Surveillance Recommendations for[...]